Edwards Lifesciences (EW) Net Cash Flow (2009 - 2026)

Edwards Lifesciences' Net Cash Flow history runs 18 years deep, the most recent figure standing at -$500.2 million for Q1 2026.

• In Q1 2026, Net Cash Flow fell 564.44% year-over-year to -$500.2 million; the TTM figure through Mar 2026 stood at -$682.4 million (down 135.75% YoY), while the FY2025 annual figure was -$74.5 million, down 103.98% from the prior year.
• Net Cash Flow was -$500.2 million for Q1 2026 at Edwards Lifesciences, down from $241.2 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $2.1 billion in Q3 2024 to a low of -$675.6 million in Q4 2024.
• Historically, Net Cash Flow has averaged $90.7 million across 5 years, with a median of $108.0 million in 2023.
• The sharpest annual moves came in 2023 and 2026: Net Cash Flow soared 827.79% in 2023, then sank 564.44% in 2026.
• A 5-year view of Net Cash Flow shows it stood at -$460.9 million in 2022, then jumped by 43.05% to -$262.5 million in 2023, then tumbled by 157.37% to -$675.6 million in 2024, then surged by 135.7% to $241.2 million in 2025, then plunged by 307.38% to -$500.2 million in 2026.
• The last three Net Cash Flow figures came in at -$500.2 million (Q1 2026), $241.2 million (Q4 2025), and -$594.2 million (Q3 2025), per Business Quant data.